Pradhan et al. have demonstrated a 62% increase in the risk of future ASCVD events (3.6% annual event rate) in statin and PCSK9-treated patients who have achieved median LDL-C of 1.07 mmol/L (41.7 mg/dl) but have raised high-sensitivity C-reactive protein (>3 mg/L) suggesting complex interplay of multiple residual ASCVD risk factors in the pathogenesis of ASCVD (88). Here, PCSK9 is linked to atherosclerosis.